TBPH
Theravance Biopharma
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: TBPH
- PE Ratio
The PE ratio for Theravance Biopharma stock stands at 7.01 as of Jun 3, 2026. This is calculated based on the current EPS of $2.27 and the stock price of $15.92 per share. A decrease of 67% has been recorded in the P/E ratio compared to the average of 21.3 of the last 4 quarters.
TBPH PE ratio history
Over the last four years, the average PE ratio of Theravance Biopharma has been 11.12. The current 7.01 PE ratio is 37% below the historical average. In the past four years, TBPH's PE ratio was at its highest in the Jun 2025 quarter at 44.12, with a price of $11.03 and an EPS of $0.25. The Jun 2023 quarter recorded the bottom point at 0.88, with a price of $10.35 and an EPS of $11.7.
Theravance Biopharma PE ratio by year
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 8.91 | N/A | $18.71 | $2.1 |
| 2024 | N/A | N/A | $9.41 | -$1.15 |
| 2023 | N/A | N/A | $11.24 | -$1 |
| 2022 | 0.95 | N/A | $11.22 | $11.85 |
| 2021 | N/A | N/A | $11.05 | -$2.87 |
| 2020 | N/A | N/A | $17.77 | -$4.46 |
| 2019 | N/A | N/A | $25.89 | -$4.25 |
| 2018 | N/A | N/A | $25.59 | -$3.99 |
| 2017 | N/A | N/A | $27.89 | -$5.45 |
| 2016 | N/A | N/A | $31.88 | -$4.26 |
| 2015 | N/A | N/A | $16.39 | -$5.34 |
| 2014 | N/A | N/A | $14.92 | -$7.46 |
| 2013 | N/A | N/A | N/A | -$4.92 |
| 2012 | N/A | N/A | N/A | -$0.3 |
| 2011 | N/A | N/A | N/A | N/A |
Theravance Biopharma PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2026 | 7.15 | -19.75% | $16.23 | $2.27 |
| Dec 2025 | 8.91 | -64.6% | $18.71 | $2.1 |
| Sep 2025 | 25.17 | -42.95% | $14.6 | $0.58 |
| Jun 2025 | 44.12 | N/A | $11.03 | $0.25 |
| Mar 2025 | N/A | N/A | $8.93 | -$1.18 |
| Dec 2024 | N/A | N/A | $9.41 | -$1.15 |
| Sep 2024 | N/A | N/A | $8.06 | -$1.03 |
| Jun 2024 | N/A | N/A | $8.48 | -$0.94 |
| Mar 2024 | N/A | N/A | $8.97 | -$0.88 |
| Dec 2023 | N/A | N/A | $11.24 | -$1 |
| Sep 2023 | N/A | N/A | $8.63 | -$0.61 |
| Jun 2023 | 0.88 | -3.3% | $10.35 | $11.7 |
| Mar 2023 | 0.91 | -4.21% | $10.85 | $11.87 |
| Dec 2022 | 0.95 | 5.56% | $11.22 | $11.85 |
| Sep 2022 | 0.9 | N/A | $10.14 | $11.28 |
TBPH Price vs fair value
TBPH average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
Currently, TBPH's PE ratio is lower than the 3, 5 and 10-year averages.
PE comparison
With a P/E of 7.01, TBPH stands below the Healthcare sector and the industry average. Compared to its Healthcare sector average of 23.02, Theravance Biopharma's P/E is 70% lower.
TBPH PE vs peers
TBPH's PE ratio is lower than its peer stock CPRX.
| Stock name | PE ratio | Market cap |
|---|---|---|
| TBPH Theravance Biopharma Inc | 7.22 | $844.44M |
| CPRX Catalyst Pharmaceuticals Inc | 17.27 | $3.83B |
| MDWD MediWound Ltd | N/A | $186.03M |
| LITS Lite Strategy Inc. | N/A | $28.14M |
Frequently asked questions
What is Theravance Biopharma's PE ratio?
TBPH's price to earnings ratio is 7.01 as of Jun 3, 2026.
What is the 3-year average PE ratio for Theravance Biopharma (TBPH)?
The 3-year average PE ratio for TBPH stock is 17.25.
What is the 5-year average PE ratio for Theravance Biopharma (TBPH)?
The 5-year average PE ratio for TBPH stock is 11.12.
What is the highest PE ratio for TBPH?
In the last four years, the Jun 2025 quarter recorded the highest quarterly PE ratio at 44.12.
How does the current PE ratio for TBPH compare to its historical average?
The current price to earnings ratio of TBPH is 37% lower than the 4-year historical average.
Why is Theravance Biopharma's PE ratio so low?
TBPH's PE ratio is low because the stock price is relatively cheap compared to the earnings generated by the company.
How is TBPH's PE ratio calculated (Theravance Biopharma PE ratio formula)?
The PE ratio is calculated by dividing the most recent price of a stock by its trailing twelve months EPS. As of today (Jun 3, 2026), Theravance Biopharma's stock price is $15.92. The earnings per share for the trailing twelve months (TTM) ending Mar 2026 is $2.27. Therefore, Theravance Biopharma's P/E ratio for today is 7.01. PE RATIO(7.01) = STOCK PRICE($15.92) / TTM EPS($2.27)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.